Noriaki Numata
Noriaki Numata has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Shoko Yamamoto
Technical Center, Jellice Co., Ltd., 4-4-1 Sakae, Tagajo, Miyagi 985-0833, Japan
2 shared publications - Akiko Sakasai-Sakai
Department of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku, Ishikawa, 920-0293, Japan; General Medicine Center, Kanazawa Medical University Hospital, 1-1 Daigaku, Uchinada, Kahoku, Ishikawa, 920-0293, Japan
1 shared publication Fumihiro Yanbe
Technical Center, Jellice Co., Ltd., 4-4-1 Sakae, Tagajo, Miyagi 985-0833, Japan
1 shared publication- Fumio Nakamura
Department of Biochemistry, Tokyo Women’s Medical University
1 shared publication - Hidekazu Kaneko
Human Informatics and Interaction Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Central 6, 1-1-1 Higashi, Tsukuba, Japan
1 shared publication - Koji Hyodo
National Institute of Advanced Industrial Science and Technology (AIST), Ibaraki, Japan
1 shared publication
Latest Publications
- 1 February 2026
- Published by Bentham Science Publishers Ltd. in Protein & Peptide Letters
- Vol. 33 (2) , 454-464
The Glycine-Proline-Hydroxyproline Tripeptide Reduces Cell Death Caused by Glycative Stress
Introduction: Long-term intake of Collagen Tripeptide (CTP), which is rich in Glycine- X-Y sequences, improves blood vessel elasticity and reduces the serum levels of cytotoxic glyceraldehyde (GA)-derived Advanced Glycation End-Products (AGEs), also known as Toxic AGEs (TAGE). Therefore, the anti-glycation effect of CTP may be one of the mechanisms contributing to its ability to improve vascular elasticity. This study aims to investigate the antiglycation effects of the tripeptide, glycine-proline-hydroxyproline (Gly-Pro-Hyp; GPHyp), the main component of CTP, using in vitro GA glycation models and comparing its metabolite sequences. Methods: Cell viability and mRNA expression were measured in GA-treated HepG2 cells with or without the addition of GPHyp. The half-maximal inhibitory concentration (IC50) of GPHyp for inhibiting TAGE formation and for inhibiting lysozyme glycation crosslinking was evaluated. Results: Only GPHyp significantly suppressed cell death and interleukin-8 (IL-8) mRNA expression in GA-treated cells. The IC50 for TAGE production and inhibitory effect on lysozyme crosslinking demonstrated that GPHyp exhibited stronger anti-glycation effects than its metabolite amino acids and peptides. The addition of GPHyp also resulted in increased GA consumption. Analysis of the changes in GA concentrations during the reaction revealed that the addition of GPHyp significantly reduced GA levels within the first hour. Discussion: These results suggest that GPHyp possesses potent GA-scavenging activity and inhibits TAGE production, contributing to the CTP-mediated reduction in serum TAGE levels and to improvements in vascular elasticity. Conclusion: The anti-glycation effect of GPHyp may support a healthy lifestyle and warrant further investigation.
- 1 February 2026
- Published by Bentham Science Publishers Ltd. in Protein & Peptide Letters
- Vol. 33 (2) , 454-464
The Glycine-Proline-Hydroxyproline Tripeptide Reduces Cell Death Caused by Glycative Stress
Introduction: Long-term intake of Collagen Tripeptide (CTP), which is rich in Glycine- X-Y sequences, improves blood vessel elasticity and reduces the serum levels of cytotoxic glyceraldehyde (GA)-derived Advanced Glycation End-Products (AGEs), also known as Toxic AGEs (TAGE). Therefore, the anti-glycation effect of CTP may be one of the mechanisms contributing to its ability to improve vascular elasticity. This study aims to investigate the antiglycation effects of the tripeptide, glycine-proline-hydroxyproline (Gly-Pro-Hyp; GPHyp), the main component of CTP, using in vitro GA glycation models and comparing its metabolite sequences. Methods: Cell viability and mRNA expression were measured in GA-treated HepG2 cells with or without the addition of GPHyp. The half-maximal inhibitory concentration (IC50) of GPHyp for inhibiting TAGE formation and for inhibiting lysozyme glycation crosslinking was evaluated. Results: Only GPHyp significantly suppressed cell death and interleukin-8 (IL-8) mRNA expression in GA-treated cells. The IC50 for TAGE production and inhibitory effect on lysozyme crosslinking demonstrated that GPHyp exhibited stronger anti-glycation effects than its metabolite amino acids and peptides. The addition of GPHyp also resulted in increased GA consumption. Analysis of the changes in GA concentrations during the reaction revealed that the addition of GPHyp significantly reduced GA levels within the first hour. Discussion: These results suggest that GPHyp possesses potent GA-scavenging activity and inhibits TAGE production, contributing to the CTP-mediated reduction in serum TAGE levels and to improvements in vascular elasticity. Conclusion: The anti-glycation effect of GPHyp may support a healthy lifestyle and warrant further investigation.
- 1 January 2022
- Published by Elsevier in Behavioural Brain Research
- Vol. 417, 113561
Oral administration of cyclic glycyl-proline facilitates task learning in a rat stroke model
- 1 January 2022
- Published by Elsevier in Behavioural Brain Research
- Vol. 417, 113561
Oral administration of cyclic glycyl-proline facilitates task learning in a rat stroke model
- 1 February 2013
- Published by Elsevier in Journal of Dermatological Science
- Vol. 69 (2) , e33
Oral administration of collagen tripeptide improves dryness and pruritus in the acetone-induced dry skin model
- 1 February 2013
- Published by Elsevier in Journal of Dermatological Science
- Vol. 69 (2) , e33
Oral administration of collagen tripeptide improves dryness and pruritus in the acetone-induced dry skin model